Tech Center 1600 • Art Units: 1648 1671
This examiner grants 76% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18029467 | METHODS FOR DETECTING ANTIBODIES | Non-Final OA | The Regents of the University of California |
| 18050806 | THERAPEUTIC AND PREVENTATIVE CANCER VACCINES | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 17819259 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18734979 | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18252800 | MODIFIED SECRETED HEPATITIS C VIRUS (HCV) E1E2 GLYCOPROTEINS AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17761371 | AN ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINE AND METHODS OF USE | Non-Final OA | Children's Medical Center Corporation |
| 18188527 | ONE-POT PATHOGEN DETECTION SYSTEM AND METHOD FOR REAL-TIME LATERAL FLOW ASSAY | Non-Final OA | City University of Hong Kong |
| 17733566 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Final Rejection | PFIZER INC. |
| 17749716 | ASSAYS FOR VIRAL STRAIN DETERMINATION | Final Rejection | Meso Scale Technologies, LLC. |
| 18654304 | Antigenic Peptides For Prevention And Treatment Of Cancer | Non-Final OA | ENTEROME S.A. |
| 18313158 | ADENO-ASSOCIATED VIRUS VECTORS | Non-Final OA | The Children's Medical Center Corporation |
| 18621631 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | Final Rejection | VERIMMUNE INC. |
| 18407958 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 17618283 | MUCOSAL VACCINE FORMULATIONS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17786631 | Nucleic acid vaccination using neo-epitope encoding constructs | Non-Final OA | Evaxion Biotech A/S |
| 18461321 | RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS | Final Rejection | Wisconsin Alumni Research Foundation (WARF) |
| 17283658 | RECOMBINANT RSV LIVE VACCINE STRAIN AND PRODUCTION METHOD THEREFOR | Non-Final OA | SK BIOSCIENCE CO., LTD. |
| 18337861 | Compositions and Methods for Producing Recombinant AAV | Final Rejection | Sangamo Therapeutics, Inc. |
| 17612179 | Yeast-Based Oral Vaccination | Final Rejection | ESPEROVAX INC. |
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | Non-Final OA | Greffex, Inc. |
| 18022428 | ASSAY FOR SARS-CoV-2 INFECTION OF VULNERABLE HUMAN CELLS | Non-Final OA | The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads |
| 17996300 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) | Final Rejection | ÖSTERREICHISCHE AGENTUR FÜR GESUNDHEIT UND ERNÄHRUNGSSICHERHEIT GMBH |
| 17932320 | NON-NEUROINVASIVE VIRUSES AND USES THEREOF | Non-Final OA | TRUSTEES OF TUFTS COLLEGE (AKA TUFTS UNIVERSITY) |
| 17288656 | HYALURONIC ACID AS A NATURAL ADJUVANT FOR PROTEIN AND PEPTIDE-BASED VACCINES | Non-Final OA | ISTITUTO ONCOLOGICO VENETO IOV-IRCCS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy